Home | Sitemap | Careers | Contact Us   Search           Select a Country Ranbaxy Global Ranbaxy USA Ranbaxy Canada Ranbaxy Germany     -SELECT- Gastrointestinal (GI) Cold Cough and Allergy Analgesics     -SELECT- Ranitidine, 75 mg Acid Reducer Tablets Anti-Diarrheal Caplets Gas Relief Softgel Cetirizine HCI 1 mg/ml.Oral Solution Cetirizine HCI Tablets,10 mg Allergy Relief Loratadine Tablets 10 mg Allergy Relief Loratadine Orally Disintegraing Tablets 10 mg DayTime Liquid Caps NightTime Liquid Caps Loratadine Tablets, 10mg Pseudoephedrine 120mg Nasal Decongestant Tablets Compare to the Active Ingredients in Claritin D24® Tablets Arthritis Pain Relief Caplets 8HR Pain Relief Caplets Allergy Relief Loratadine Orally Disintegrating Tablets 10 mg     Home > Newsroom   Newsroom April 25, 2008 Ranbaxy receives final US FDA approval to manufacture and market Cetirizine Hydrochloride Oral Solution   Dec 31, 2007 Ranbaxy Receives Final approval to manufacture and market cetirizine hydrochloride tablets (OTC), 5mg and 10mg.     April 12, 2007 Ranbaxy receives FDA approval to market Loratadine Orally Disintegrating Tablets     Sep 11, 2006 Ranbaxy receives FDA approval to market Loperamide hydrochloride and Simethicone tablets     Aug 1, 2006 Ranbaxy Subsidiary Ohm Labs Receives Prestigious “Private Label Supplier of the Year Award” from AmerisourceBergen   Media Contacts Chuck Caprariello Vice President, Corporate Communications and Government Affairs Phone: (609)720-5615 chuck.caprariello@ranbaxy.com